- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02421835
Olive Leaf Extract as Part of a Healthy Lifestyle in the Reduction of Blood Pressure
Hypertension affects about 30% of the United Kingdom population and is causally implicated in the aetiology of renal disease, cardiovascular disease and stroke. Ageing, obesity, a poor diet and low levels of physical activity are all risk factors. Studies have shown that adherence to a Mediterranean diet is protective against hypertension and its associated morbidities; olive oil is believed to be a key beneficially bioactive component of that diet. As a source of lipids olive oil is an unremarkable blend of monounsaturated, polyunsaturated and saturated fatty acids; it is however rich in phenolic compounds, principally oleuropein and hydroxytyrosol, which may be of benefit to health. A recent randomised intervention trial in predominantly hypertensive volunteers showed that adherence to a Mediterranean diet supplemented with extra virgin olive oil, reduced blood pressure and other measures of cardiovascular disease risk. Olive phenolics can be extracted cheaply from the waste products of olive oil manufacture, such as the plant leaf and these are used as dietary supplements. In intervention studies in hypertensive or borderline hypertensive patients, olive leaf extract consumption has been shown to reduce blood pressure.
Another intervention with established efficacy for improving blood pressure is to increase physical activity. The 'Start Active, Stay Active', Chief Medical Officers report on physical activity recommends that adults achieve 150 minutes of moderate intensity physical activity per week, while data in that report suggest that fewer than 40% of adult men and 30% of adult women achieve these targets. Adherence to the physical activity guidelines may in fact be much worse in sub-sections of the population at higher risk of hypertension.
From a public health perspective, holistic guidelines for the prevention of hypertension, or its early diagnosis and management, based around a healthy diet and lifestyle are preferable to pharmaceutical intervention. Lifestyle interventions are economically favourable and they come with fewer side effects and perhaps wider health benefits than antihypertensive drugs.
The aim of the study is to evidence the synergistic benefits of consuming plant (and specifically olive) phenolics alongside achieving the recommended guidelines for physical activity in individuals with elevated blood pressure.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Berkshire
-
Reading, Berkshire, United Kingdom, RG6 6AP
- Hugh Sinclair Unit of Human Nutrition
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women
- 25-70y
- BMI >25kg/m2
- Not having suffered a myocardial infarction/stroke in the past 12 months
- Not diabetic (diagnosed or fasting glucose > 7 mmol/l) or suffer from other endocrine disorders
- Not suffering from renal or bowel disease or have a history of cholestatic liver or pancreatitis
- Not on drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation
- No history of alcohol misuse
- Not planning or on a weight reducing regime
- Not taking any fish oil, fatty acid or vitamin and mineral supplements
- Non smokers
Exclusion Criteria:
- Use of antibiotics within the previous 6 months
- History of alcohol or drug abuse
- Intake of any experimental drug within 4 weeks of the start of the study
- Excessive alcohol consumption (more than 21 units/wk male, 15 units/wk female)
- Females who are breast-feeding, may be pregnant, or of child-bearing potential and not using effective contraceptive precautions
- Have had recently (in the last 5 years) major surgery, which might limit participation in, or completion of, the study.
- On drug treatment for high blood fats, high blood pressure and blood clotting.
- Physical or mental diseases that are likely to limit participation or completion of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo control
2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
|
700 mg Maltodextrin per day
Other Names:
|
Active Comparator: Olive leaf extract
2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
|
132 mg of oleuropein per day suspended in olive leaf extract 700 mg
|
Placebo Comparator: Physical activity
2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
|
700 mg Maltodextrin per day
Other Names:
|
Active Comparator: Physical activity and olive leaf extract
2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
|
132 mg of oleuropein per day suspended in olive leaf extract 700 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure measured via 24 hour ambulatory blood pressure monitors
Time Frame: 12 weeks
|
measured using the ScanMed Oscillometric Ambulatory blood pressure deviceVolunteers will be asked to wear the device which will be programmed to record BP measurements every 30 minutes during the day (7am-10pm) and every hour by night (10pm-7am)
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average plasma glucose concentration
Time Frame: 12 weeks
|
a measure of chronic blood sugar control) by measuring of glycated haemoglobin (HbA1c)
|
12 weeks
|
Vascular function assessed by pulse wave velocity (PWV)
Time Frame: 12 weeks
|
12 weeks
|
|
Plasma biomarkers of endothelial function including nitric oxide, vascular cell adhesion molecule (VCAM), Inter-Cellular Adhesion Molecule (ICAM), E-selectin, von Willebrand factor
Time Frame: 12 weeks
|
12 weeks
|
|
Fasting lipid profile including measures of total, low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol, triglycerides and non-esterified fatty acids
Time Frame: 12 weeks
|
12 weeks
|
|
Indices of insulin resistance derived from fasted measures of glucose, insulin and non-esterified fatty acids (revised QUICKI statistical analysis)
Time Frame: 12 weeks
|
12 weeks
|
|
Haemostatic factors including Plasminogen activator inhibitor-1 (PAI-1)
Time Frame: 12 weeks
|
12 weeks
|
|
Inflammatory biomarkers including the acute phase proteins, C-reactive protein (CRP), tumour necrosis factor alpha (TNFα), Interleukin-6 (IL6)
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel Commane, PhD, Reading University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OLE Chronic Study 2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre Hypertension
-
Skidmore CollegeAmerican Heart AssociationNot yet recruitingHypertension | Pre HypertensionUnited States
-
University of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertension | Pre-HypertensionUnited States
-
University of VermontUnknown
-
Riphah International UniversityRecruitingPre HypertensionPakistan
-
University Institute of MaiaUniversity of Connecticut; Aveiro University; Hospital Infante D. Pedro, Centro... and other collaboratorsCompletedHypertension | Pre-HypertensionUnited States, Portugal
-
Florida Heart Research InstituteTerminatedPre-HypertensionUnited States
-
University of MinnesotaCompleted
-
University of NebraskaNational Institute of Nursing Research (NINR)CompletedPre-HypertensionUnited States
-
BayerCompletedHypertension | Postmenopause | Pre-HypertensionUnited States
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States